Erratum to Circulating endothelial progenitor cells in gynaecological cancer (Journal of International Medical Research, 41, 2(293-299), 10.1177/0300060513476999);Circulating endothelial progenitor cells in gynaecological cancer

Journal of International Medical Research

Volumn 41, Issue 2, 2013, Pages 293-299

  Kim, Yoon Byoung ^a   Chung, Ye Won ^a   Bae, Hyo Sook ^a   Lee, Jae Kwan ^a   Lee, Nak Woo ^a   Lee, Kyu Wan ^a   Song, Jae Yun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cervical cancer; Circulating endothelial progenitor cells; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; CD34 ANTIGEN; CISPLATIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL COUNT; CELL ISOLATION; CHEMORADIOTHERAPY; CHEMOSURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84878348242     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513491038     Document Type: Erratum

References (25)

1. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
2. Dome B, Dobos J, Tovari J, et al. Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 2008; 73: 186-193.
3. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
4. Goon PK, Lip GY, Boos CJ, et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79-88.
5. George AL, Bangalore-Prakash P, Rajoria S, et al. Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol 2011; 4: 24.
6. Masouleh BK, Baraniskin A, Schmiegel W, et al. Quantification of circulating endothelial progenitor cells in human peripheral blood: establishing a reliable flow cytometry protocol. J Immunol Methods 2010; 357: 38-42.
7. Goon PK, Lip GY, Stonelake PS, et al. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 2009; 11: 771-779.
8. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008; 107: 133-138.
9. Blann AD, Balakrishnan B, Shantsila E, et al. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate 2011; 71: 1047-1053.
10. Morita R, Sato K, Nakano M, et al. Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. J Cancer Res Clin Oncol 2011; 137: 1849-1857.
11. Su Y, Zheng L, Wang Q, et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res 2010; 29: 27.
12. Oki Y and Younes A. Endothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica 2007; 92: 433-434.
13. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003; 9: 377-382.
14. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63: 8345-8350.
15. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-4346.
16. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7: 101-111.
17. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106: 3058-3061.
18. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787.
19. Dome B, Timar J, Ladanyi A, et al. Circulating endothelial cells, bone marrowderived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 2009; 69: 108-124.
20. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-264.
21. Dong F and Ha XQ. Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy. Chin Med J (Engl) 2010; 123: 2454-2460.
22. Khan SS, Solomon MA and McCoy JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005; 64: 1-8.
23. Raida M, Weiss T, Leo C, et al. Circulating endothelial progenitor cells are inversely correlated with the median oxygen tension in the tumor tissue of patients with cervical cancer. Oncol Rep 2006; 16: 597-601.
24. Li A, Cheng XJ, Moro A, et al. CXCR2- dependent endothelial progenitor cell mobilization in pancreatic cancer growth. Transl Oncol 2011; 4: 20-28.
25. Garmy-Susini B and Varner JA. Circulating endothelial progenitor cells. Br J Cancer 2005; 93: 855-858.